TNF and uveitis: The anti-TNFα antibodies currently in clinical use (in some cases for the treatment of forms of uveitis, in addition to other conditions) are administered subcutaneously or intravenously, and typically achieve serum concentrations in the μg/mL range13,18–20 but, in this study, the maximum concentration was around 1 ng/mL.